Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumour-Burden Follicular Lymphoma: Final Results of a Randomised Phase 3 Study

Abbreviations: ADA  = antidrug antibody; CI = confidence interval; FL = follicular lymphoma; GELF = Groupe D'Etude des Lymphomes Folliculaires; IRR = infusion-related reaction; ITT = intention-to-treat; IV = intravenously; LTBFL = low-tumour-burden follicular lymphoma; MP1 = mainten ance period 1; MP2 = maintenance period 2; NCCN = National Comprehensive Cancer Network; ORR = overall response rate; OS = overall survival; PFS = progression-free survival; RA = rheumatoid arthritis; TEAE = treatment-emergent adverse event; TESAE = treatment-emergent serious adverse event; TTE = time-to-event; TTP = time to progression.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2021 Category: Hematology Authors: Larry W. Kwak, Juan-Manuel Sancho, Seok-Goo Cho, Hideyuki Nakazawa, Junji Suzumiya, Gayane Tumyan, Jin Seok Kim, Tobias Menne, Jos é Mariz, Nikolai Ilyin, Wojciech Jurczak, Aurelio Lopez Martinez, Olga Samoilova, Edvard Zhavrid, Eduardo Yañez Ruiz, Mare Source Type: research